Crowder's research focuses on beta-lactams, which are the largest class of clinical antibiotics that are used to treat bacterial infections. Bacteria commonly produce beta-lactamases, enzymes which inactivate most, if not all, beta-lactam antibiotics.
Increasingly more bacteria have begun producing metallo-beta-lactamases, which cannot be combatted with any available drugs. New Delhi metallo-beta-lactamases (NDMs) have mutated into at least 20 different variants found in patients. Crowder and his research team, made up of groups from Miami, Case Western Reserve University, and University of Texas, have isolated and characterized 17 of these NDM variants.
"Metallo-beta-lactamases are a huge clinical concern," Crowder said. "This research provides explanation for why NDMs are evolving to be an even more significant clinical problem."